Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?

VanEck Biotech ETF (BBH) looks better for 2026 biotech exposure, with BBH delivering higher returns than Invesco S&P 500 Equal Weight Health Care ETF (RSPH) in all periods except 5- and 10-year. Despite higher risk (5-year max drawdown of -39.9% vs -22.0%), BBH’s 3-year/5-year/10-year returns were 9.8%/0.6%/7.8% versus RSPH’s 4.4%/3.3%/8.9%. BBH also has the lower fee (0.35% vs 0.40%) but a lower trailing dividend yield (0.50% vs 0.70%).

Analysis

This is less a fundamental healthcare call than a vehicle-choice signal. BBH is effectively a high-conviction bet on a handful of cash-generative biotech incumbents, while RSPH is the cleaner way to own healthcare beta without making one pipeline or one reimbursement headline the whole trade. The first-order winner from any passive flow is AMGN/GILD/VRTX; the second-order loser is subscale biotech, which gets starved of capital because BBH’s structure channels demand into the same few large names rather than broadening the risk-on impulse.

The real catalyst path is macro and policy, not this article: if real yields back up or drug-pricing rhetoric intensifies, BBH should feel it faster than RSPH because concentration magnifies factor drawdowns. Over 1-3 months, BBH’s performance will likely hinge on whether biotech breadth improves or remains narrow; narrow breadth favors mean reversion against BBH because top-heavy funds can outperform only while the same leaders keep printing revisions. Over 6-18 months, M&A and clinical readouts matter more, but the asymmetry remains that BBH can gap down on a single negative readout, whereas RSPH disperses that idiosyncratic risk across services/tools and broader healthcare exposure.

Contrarian view: the market may be overpricing BBH’s recent relative strength as if it were a sector thesis, when it is really a concentration thesis. For investors using healthcare as a defensive allocation, RSPH is the more durable risk-adjusted vehicle; for tactical biotech exposure, BBH is acceptable only if you have a clear catalyst stack and a tight risk budget. The opportunity is in relative value, not outright sector beta.

Key Decisions for Investors

• Prefer RSPH over BBH for a 6-18 month healthcare allocation; it is the cleaner defensive exposure if rates stay elevated and political pressure on drug pricing persists.
• Pair trade: long RSPH / short BBH over 1-3 months if biotech breadth remains narrow; target 4-7% relative outperformance for RSPH, stop if BBH outperforms by ~5% on positive rate or M&A news.
• If you want tactical biotech upside, buy BBH only on a 3-5% pullback and only after confirming lower yields or an active M&A/readout window; otherwise the concentration risk is not being paid enough.
• Overweight the BBH top holdings basket conceptually — AMGN, GILD, VRTX — only as a short-duration trade tied to earnings revision momentum; avoid treating BBH as a diversified healthcare substitute.
• Watch CRL and MRNA as sentiment canaries: sustained weakness there would argue the market is not rewarding broad healthcare risk, which would strengthen the case to fade BBH strength.